NCT00318500

Brief Summary

The purpose of the study is to evaluate the efficacy and safety of two doses of ERB-041 (75 mg and 150 mg) relative to placebo on the relief of endometriosis-related symptoms (dysmenorrhea, pelvic pain, and deep dyspareunia) in reproductive aged women.

Trial Health

93
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started May 2006

Shorter than P25 for phase_2

Geographic Reach
7 countries

70 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 24, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 26, 2006

Completed
5 days until next milestone

Study Start

First participant enrolled

May 1, 2006

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2006

Completed
Last Updated

December 10, 2007

Status Verified

December 1, 2007

First QC Date

April 24, 2006

Last Update Submit

December 7, 2007

Conditions

Keywords

EndometriosisDysmenorrheaPelvic painDyspareunia

Outcome Measures

Primary Outcomes (1)

  • severity scores for dysmenorrhea, pelvic pain and deep dyspareunia from baseline through 12 weeks of treatment using the B & B scale administered by the investigator

Secondary Outcomes (3)

  • change in severity scores for pelvic tenderness and pelvic induration during 12 weeks of treatment

  • change in rescue medication use

  • change in health related quality of life questionnaires

Interventions

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Surgical diagnosis of endometriosis within the last 10 years
  • Sexually active, nonpregnant, nonlactating women (18-45 years) with regular menstrual cycles who are willing to use non-hormonal contraception

You may not qualify if:

  • Conditions requiring the use of chronic pain therapy
  • Prophylactic use of analgesics to avoid endometriosis-related pain

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (70)

Unknown Facility

Montgomery, Alabama, 36116, United States

Location

Unknown Facility

Chandler, Arizona, 85225, United States

Location

Unknown Facility

Phoenix, Arizona, 85032, United States

Location

Unknown Facility

Phoenix, Arizona, 85035, United States

Location

Unknown Facility

Tucson, Arizona, 85712, United States

Location

Unknown Facility

San Francisco, California, 94115, United States

Location

Unknown Facility

Vista, California, 92083, United States

Location

Unknown Facility

Denver, Colorado, 80202, United States

Location

Unknown Facility

Denver, Colorado, 80206, United States

Location

Unknown Facility

New Britain, Connecticut, 06050, United States

Location

Unknown Facility

Clearwater, Florida, 33759, United States

Location

Unknown Facility

New Port Richey, Florida, 34652, United States

Location

Unknown Facility

Plantation, Florida, 33324, United States

Location

Unknown Facility

Venice, Florida, 34285, United States

Location

Unknown Facility

West Palm Beach, Florida, 33401, United States

Location

Unknown Facility

West Palm Beach, Florida, 33409, United States

Location

Unknown Facility

Marietta, Georgia, 30066, United States

Location

Unknown Facility

Idaho Falls, Idaho, 83404, United States

Location

Unknown Facility

Oak Brook, Illinois, 60523, United States

Location

Unknown Facility

Evansville, Indiana, 47714, United States

Location

Unknown Facility

Reno, Nevada, 89502, United States

Location

Unknown Facility

Lawrenceville, New Jersey, 08648, United States

Location

Unknown Facility

Durham, North Carolina, 27710, United States

Location

Unknown Facility

New Bern, North Carolina, 28562, United States

Location

Unknown Facility

Raleigh, North Carolina, 27612, United States

Location

Unknown Facility

Winston-Salem, North Carolina, 27103, United States

Location

Unknown Facility

Cleveland, Ohio, 44122, United States

Location

Unknown Facility

Miamisburg, Ohio, 45342, United States

Location

Unknown Facility

Oklahoma City, Oklahoma, 73112, United States

Location

Unknown Facility

Portland, Oregon, 97210, United States

Location

Unknown Facility

Abington, Pennsylvania, 19001, United States

Location

Unknown Facility

Lansdale, Pennsylvania, 19446, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19107, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19114, United States

Location

Unknown Facility

Pittsburgh, Pennsylvania, 15243, United States

Location

Unknown Facility

Columbia, South Carolina, 29201, United States

Location

Unknown Facility

Greenville, South Carolina, 29607, United States

Location

Unknown Facility

Bristol, Tennessee, 37620, United States

Location

Unknown Facility

Chattanooga, Tennessee, 37403, United States

Location

Unknown Facility

Memphis, Tennessee, 38119, United States

Location

Unknown Facility

Corpus Christi, Texas, 78414, United States

Location

Unknown Facility

San Antonio, Texas, 78229, United States

Location

Unknown Facility

West Valley City, Utah, 84120, United States

Location

Unknown Facility

Norfolk, Virginia, 23507, United States

Location

Unknown Facility

Richmond, Virginia, 23233, United States

Location

Unknown Facility

Richmond, Virginia, 23294, United States

Location

Unknown Facility

Virginia Beach, Virginia, 23456, United States

Location

Unknown Facility

Renton, Washington, 98055, United States

Location

Unknown Facility

Madison, Wisconsin, 53792, United States

Location

Unknown Facility

Randwick, New South Wales, 2031, Australia

Location

Unknown Facility

Sydney, New South Wales, 200, Australia

Location

Unknown Facility

Richmond, Victoria, 3121, Australia

Location

Unknown Facility

Nedlands, Western Australia, 6009, Australia

Location

Unknown Facility

Herestraat, Leuven, 3000, Belgium

Location

Unknown Facility

Calgary, Alberta, T2N 4L7, Canada

Location

Unknown Facility

Vancouver, British Columbia, V6Z 1Y6, Canada

Location

Unknown Facility

Winnipeg, Manitoba, R3A 1R9, Canada

Location

Unknown Facility

Halifax, Nova Scotia, B3H 2N1, Canada

Location

Unknown Facility

London, Ontario, N6A 4V2, Canada

Location

Unknown Facility

Toronto, Ontario, M5B 1W8, Canada

Location

Unknown Facility

Saskatoon, Saskatchewan, S7K 1N4, Canada

Location

Unknown Facility

Hong Kong, Hong Kong

Location

Unknown Facility

Cape Town, Capetown, 7925, South Africa

Location

Unknown Facility

Port Elizabeth, Eastern Cape, 6001, South Africa

Location

Unknown Facility

Roodepoort, Jgb Gauteng, 1724, South Africa

Location

Unknown Facility

Durban, KwaZulu-Natal, 4320, South Africa

Location

Unknown Facility

Nottingham, Nottinghamshire, NG7 2UH, United Kingdom

Location

Unknown Facility

Glasgow, Scotland, G51 4TF, United Kingdom

Location

Unknown Facility

Sheffield, South Yorshire, S10 2SF, United Kingdom

Location

Unknown Facility

Swindon, Wiltshire, SN3 6BD, United Kingdom

Location

MeSH Terms

Conditions

DysmenorrheaDyspareuniaEndometriosisPelvic Pain

Interventions

ERB 041

Condition Hierarchy (Ancestors)

Menstruation DisturbancesPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and SymptomsGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesGenital Diseases, MaleSexual Dysfunction, PhysiologicalMale Urogenital DiseasesSexual Dysfunctions, PsychologicalMental Disorders

Study Officials

  • Medical Monitor

    Wyeth is now a wholly owned subsidiary of Pfizer

    STUDY DIRECTOR
  • Trial Manager

    For United Kingdom, ukmedinfo@wyeth.com

    PRINCIPAL INVESTIGATOR
  • Trial Manager

    For Australia and Hong Kong, medinfo@wyeth.com

    PRINCIPAL INVESTIGATOR
  • Trial Manager

    For South Africa, ZAFinfo@wyeth.com

    PRINCIPAL INVESTIGATOR
  • Trial Manager

    For Belgium, trials-BEL@wyeth.com

    PRINCIPAL INVESTIGATOR
  • Trial Manager

    For Canada, clintrialparticipation@wyeth.com

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

April 24, 2006

First Posted

April 26, 2006

Study Start

May 1, 2006

Study Completion

December 1, 2006

Last Updated

December 10, 2007

Record last verified: 2007-12

Locations